论文部分内容阅读
目的:探讨噻哗烷二酮类胰岛素增敏剂罗格列酮和二甲双胍联合用药对2型糖尿病的治疗效果。方法:观察38例2型糖尿病患者治疗前和治疗12周后两组的空腹血糖(FBG)、餐后2 h血糖(PBG)、空腹胰岛素(FINS)、甘油三酯各项指标,并监测肝、肾功能。结果:治疗12周后,试验前后对比,FBG、PBG甘油三酯水平的差异有统计学意义(P<0.01);FINS水平的差异有统计学意义(P<0.05)。试验前后对比,餐后2 h胰岛素、体重改变不明显,其差异无统计学意义。肝、肾功能无损害。结论:罗格列酮与二甲双胍联用治疗2型糖尿病疗效确切,可改善胰岛素抵抗,使胰岛β细胞功能得到部分改善,减缓并发症出现,降低不良反应发生,从而改善糖尿病患者的生活质量。
Objective: To investigate the therapeutic effect of thiazolidinedione, a sensitizer of rosiglitazone and metformin, on type 2 diabetes mellitus. Methods: The fasting blood glucose (FBG), postprandial 2h blood glucose (PBG), fasting insulin (FINS) and triglyceride were measured in 38 patients with type 2 diabetes before and 12 weeks after treatment. , Kidney function. Results: After 12 weeks of treatment, the levels of triglyceride in FBG and PBG were significantly different between before and after treatment (P <0.01). There was significant difference in FINS between the two groups (P <0.05). Before and after the test, insulin 2 h after meal, body weight did not change significantly, the difference was not statistically significant. Liver, kidney function without damage. Conclusion: The combination of rosiglitazone and metformin is effective in treating type 2 diabetes mellitus, which can improve insulin resistance and partially improve the function of islet β cells, slow down the complication and reduce the adverse reactions, so as to improve the quality of life of diabetic patients.